Bilimsel çalışmalar

Prof. Dr. Fatih Demirkan

204 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Granulocytic sarcoma with unusual localizations (breast and stomach) without bone marrow involvement after the allogeneic transplantation

    Journal of Clinical and Medical Images Case Reports, 2022

    DOI 10.55920/2771-019x/1068 Kaynak: OpenAlex

  2. New Treatment Approaches in Relapsing/Refractory Primary Central Nervous System Lymphomas

    Annals of Medical Research, 2022

    DOI 10.5455/annalsmedres.2022.01.042 Açık erişimli tam metinKaynak: OpenAlex

  3. Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy

    Indian Journal of Hematology and Blood Transfusion, 2021

    DOI 10.1007/s12288-021-01466-1 PMID 35496952 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  4. Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential

    Transfusion and Apheresis Science, 2021

    DOI 10.1016/j.transci.2021.103247 PMID 34462217 2 atıf (Europe PMC) Kaynak: ORCID

  5. Therapeutic plasma exchange in neurological diseases: Eleven years experience at a tertiary care center in Turkey

    Therapeutic Apheresis and Dialysis, 2021

    DOI 10.1111/1744-9987.13703 PMID 34173719 15 atıf (OpenAlex) Kaynak: OpenAlex

  6. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

    Annals of Hematology, 2021

    DOI 10.1007/s00277-021-04536-6 PMID 34018029 20 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  7. Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?

    Molecular Cytogenetics, 2021

    DOI 10.1186/s13039-020-00522-1 PMID 33407772 18 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  8. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

    Advances in Therapy, 2021

    DOI 10.1007/s12325-020-01601-w PMID 33474705 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  9. Guillain Barré Syndrome in a Multiple Myeloma Patient After the Autologous Transplantation: A Case Report

    Akdeniz Medical Journal, 2021

    DOI 10.53394/akd.981986 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  10. Granulocytic Sarcoma with unusual localizations (breast and stomach) without Bone Marrow involvement after the Allogeneic Transplantation

    Journal of Clinical and Medical Images Case Reports, 2021

    DOI 10.55920/2771-019x/1044 Kaynak: OpenAlex

  11. Retrospective Evaluation of Patients with and without Primary Antifungal Prophylaxis During Remission Induction Chemotherapy in Patients with Acute Myeloid Leukemia

    LLM Dergi, 2020

    DOI 10.5578/llm.69347 Açık erişimli tam metinKaynak: ORCID

  12. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

    Leukemia & lymphoma/Leukemia and lymphoma, 2020

    DOI 10.1080/10428194.2020.1795159 PMID 32762271 47 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  13. Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

    Blood, 2020

    DOI 10.1182/blood-2020-134437 5 atıf (OpenAlex) Kaynak: OpenAlex

  14. CLL-395: Real-World Data from the Turkish National Chronic Lymphocytic Leukemia Registry

    Clinical Lymphoma Myeloma & Leukemia, 2020

    DOI 10.1016/s2152-2650(20)30806-5 2 atıf (OpenAlex) Kaynak: OpenAlex

  15. What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?

    Indian Journal of Transplantation, 2020

    DOI 10.4103/ijot.ijot_15_19 Açık erişimli tam metinKaynak: OpenAlex

  16. Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e20011 Kaynak: OpenAlex

  17. CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

    Clinical Lymphoma Myeloma & Leukemia, 2020

    DOI 10.1016/s2152-2650(20)30788-6 Kaynak: OpenAlex

  18. Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study

    Turkish Journal of Hematology, 2019

    DOI 10.4274/tjh.galenos.2019.2019.0008 PMID 31131598 Açık erişimli tam metinKaynak: OpenAlex

  19. Turkish Acute Lymphoblastic Leukemia Registry, Retrospective Phase Data

    Blood, 2019

    DOI 10.1182/blood-2019-126006 Kaynak: OpenAlex

  20. The Turkish experience with therapeutic plasma exchange: A national survey

    Transfusion and Apheresis Science, 2019

    DOI 10.1016/j.transci.2019.04.015 PMID 31036516 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  21. Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2019

    DOI 10.4274/tjh.galenos.2019.2018.0219 PMID 30724061 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  22. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

    The Lancet Haematology, 2019

    DOI 10.1016/s2352-3026(18)30217-5 PMID 30642819 195 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  23. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

    Haematologica, 2019

    DOI 10.3324/haematol.2019.223743 PMID 31413095 8 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

    Pharmaceutical Research, 2019

    DOI 10.1007/s11095-019-2605-8 PMID 31044267 6 atıf (OpenAlex) Kaynak: OpenAlex

  25. IBRUTINIB DECREASES OBINUTUZUMAB‐INDUCED SECRETION OF CYTOKINES ASSOCIATED WITH INFUSION‐RELATED REACTIONS IN PATIENTS WITH CLL: ANALYSIS FROM THE ILLUMINATE STUDY

    Hematological Oncology, 2019

    DOI 10.1002/hon.27_2630 4 atıf (OpenAlex) Kaynak: OpenAlex

  26. Demographic, clinical, and genetic evaluation of patients with suspected inherited thrombophilia

    Van Medical Journal, 2019

    DOI 10.5505/vtd.2019.57625 Açık erişimli tam metinKaynak: OpenAlex

  27. Akut Myeloid Lösemi Hastalarımızın Retrospektif Değerlendirilmesi

    Çanakkale Onsekiz Mart University AVESIS, 2019

    Kaynak: OpenAlex

  28. Paroksismal Nokturnal Hemoglobinürili Olguların Değerlendirilmesi: İki Merkezin Deneyimi

    Çanakkale Onsekiz Mart University AVESIS, 2019

    Kaynak: OpenAlex

  29. A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study

    Transfusion and Apheresis Science, 2018

    DOI 10.1016/j.transci.2018.02.012 PMID 29503132 7 atıf (Europe PMC) Kaynak: OpenAlex

  30. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2018

    DOI 10.4274/tjh.2018.0071 PMID 29923493 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  31. Ulusal, Çok Merkezli Grup Uygunsuz ‘0’ Grup Kullanımının Retrospektif Değerlendirilmesi

    Bursa Uludag University - AVESIS, 2018

    Kaynak: OpenAlex

  32. ULUSAL, ÇOK MERKEZLİ GRUP UYGUNSUZ ’0’ GRUP KULLANIMININ RETROSPEKTİF DEĞERLENDİRİLMESİ

    Bursa Uludag University - AVESIS, 2018

    Kaynak: OpenAlex

  33. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Oncology, 2018

    DOI 10.1016/s1470-2045(18)30788-5 PMID 30522969 559 atıf (OpenAlex) Kaynak: OpenAlex

  34. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

    Leukemia, 2018

    DOI 10.1038/s41375-018-0276-9 PMID 30315239 118 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  35. Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

    Clinical Transplantation, 2018

    DOI 10.1111/ctr.13359 PMID 30053318 26 atıf (OpenAlex) Kaynak: OpenAlex

  36. Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

    Journal of Laboratory Physicians, 2018

    DOI 10.4103/jlp.jlp_36_18 PMID 30498304 20 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  37. A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience

    Indian Journal of Hematology and Blood Transfusion, 2018

    DOI 10.1007/s12288-018-0922-4 PMID 30369740 8 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  38. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies?

    Transfusion and Apheresis Science, 2018

    DOI 10.1016/j.transci.2018.02.013 PMID 29506907 2 atıf (OpenAlex) Kaynak: OpenAlex

  39. A case of langerhans cell histiocytosis associated with mantle cell lymphoma

    Journal of Surgery and Medicine, 2018

    DOI 10.28982/josam.403513 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  40. Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

    Blood, 2018

    DOI 10.1182/blood-2018-99-111370 9 atıf (OpenAlex) Kaynak: OpenAlex

  41. Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

    Blood, 2018

    DOI 10.1182/blood-2018-99-111369 3 atıf (OpenAlex) Kaynak: OpenAlex

  42. Application of apheresis science in Emergency Medicine

    Transfusion and Apheresis Science, 2018

    DOI 10.1016/j.transci.2018.02.015 PMID 29486924 1 atıf (OpenAlex) Kaynak: OpenAlex

  43. Brief biography

    Transfusion and Apheresis Science, 2018

    DOI 10.1016/j.transci.2018.02.017 Kaynak: OpenAlex

  44. TÜRKİYE DE TERAPOTİK PLAZMA EXCHANGE AKTİVİTESİ: ULUSAL ARAŞTIRMA

    AYBU AVESIS, 2018

    Kaynak: OpenAlex

  45. OTOLOG NAKİL YAPILAN MULTİPL MYELOMHASTALARINDA REİNFÜZYON GÜN SAYISININENGRAFMANA VE HASTANEDE KALIŞ SÜRESİNE ETKİSİ

    Çanakkale Onsekiz Mart University AVESIS, 2018

    Kaynak: OpenAlex

  46. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

    Transfusion and Apheresis Science, 2017

    DOI 10.1016/j.transci.2017.11.010 PMID 29153305 2 atıf (Europe PMC) Kaynak: OpenAlex

  47. Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA)

    Transfusion and Apheresis Science, 2017

    DOI 10.1016/j.transci.2017.11.025 PMID 29153306 1 atıf (Europe PMC) Kaynak: OpenAlex

  48. AKUT TRANSFÜZYON REAKSİYONLARININ ANALİZİ(TRANSFÜZYON HEMŞİRESİ ≈ HEMOVİJİLANS HEMŞİRESİMODEL PROJESİ)

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  49. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    New England Journal of Medicine, 2017

    DOI 10.1056/nejmoa1609783 PMID 28249141 2.164 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  50. IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL

    Hematological Oncology, 2017

    DOI 10.1002/hon.2438_95 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex